Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179

Circulation Research

Volumn 90, Issue 7, 2002, Pages 770-776

  Krämer, Christine ^a   Sunkomat, Julia ^a   Witte, Jana ^a   Luchtefeld, Maren ^a   Walden, Michael ^c   Schmidt, Boris ^b   Böger, Rainer H ^d   Forssmann, Wolf Georg ^c   Drexler, Helmut ^a   Schieffer, Bernhard ^a,e  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^c IPF PHARMACEUTICALS GMBH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e NONE   (Germany)

Author keywords

Atherosclerosis; Cyclooxygenase; Platelet aggregation; Prostaglandin F2 ; Thromboxane A2

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; CYCLOOXYGENASE 2; CYTOCHROME P450; DRUG METABOLITE; EXP 3179; INDOMETACIN; LIPOPOLYSACCHARIDE; LOSARTAN; MESSENGER RNA; PROSTAGLANDIN F2; PROSTAGLANDIN F2 ALPHA; THROMBOXANE A2; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

ANGIOTENSIN II; ARACHIDONIC ACID; BIOTRANSFORMATION; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROST; DRUG DESIGN; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; ISOENZYMES; LIPOPOLYSACCHARIDES; LOSARTAN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET AGGREGATION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RNA, MESSENGER; TETRAZOLES; THROMBOXANE A2; UP-REGULATION; VASOCONSTRICTOR AGENTS;

EID: 0037134412     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000014434.48463.35     Document Type: Article

References (33)

1. Regulation and metabolism of arachidonic acid
2. Atherosclerosis: An inflammatory disease
3. Platelet activation and inhibition in unstable coronary syndromes
4. Cyclooxygenase-1- and -2-dependent prostacyclin formation in patients with atherosclerosis
5. Cyclooxygenase-2 is required for tumor necrosis factor-α- and angiotensin II-mediated proliferation of vascular smooth muscle cells
6. Artherosclerosis as an infectious, inflammatory and autoimmune disease
7. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
8. Induction of cycleoxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells
9. Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride
10. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
12. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
13. 2-induced vasoconstriction in canine coronary arteries and human platelet aggregation
14. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation
15. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
16. Angiotensin II atherogenicity in apolipoprotein E deficient mice is associated with increased cellular cholesterol biosynthesis
17. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E-deficient mice
18. The role of endothelium in antithrombotic effect of the renin-angiotensin system blockade
19. Losartan inhibits experimental venous thrombosis in spontaneously hypertensive rats
20. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
21. Specific and rapid quantification of 8-iso-prostaglandin F2alpha in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry
22. Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer
23. Simple high-performance liquid chromatographic method for determination of losartan and E-3174 metabolite in human plasma, urine and dialysate
24. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
25. Angiotensin II subtype 1 receptor blockers and renal function
26. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: The LIFE study
27. Comparison of baseline data,initial course, and management: Losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial): OPTIMAAL Trial Steering Committee and Investigators: Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan
28. Angiotensin II receptor subtypes: Selective antagonists and functional correlates
29. Angiotensin II receptors and functional correlates
30. The diversified pharmacology of angiotensin II-receptor blockade
31. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism
32. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices
33. Expression of prostaglandin H2-mediated mechanism of vascular contraction in hypertensive rats: Relation to lipoxygenase and prostacyclin synthase activities